Newsroom Stay up to date with what’s happening at ONO PHARMA USA. Breadcrumb Newsroom ONO PHARMA USA Announces 2025 Golden Ticket Competition Now Accepting Applications from Innovative StartupsPress ReleaseApril 25, 2025 Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual MeetingPress ReleaseApril 24, 2025 Ono Pharmaceutical Co., Ltd. Announced 2024 Q3 Financial ResultsPress ReleaseFebruary 3, 2025 Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology AreaPress ReleaseDecember 6, 2024 ONO Pharmaceutical Co., Ltd. Announced 2024 Q2 Financial ResultsPress ReleaseOctober 31, 2024 ONO PHARMA USA Announces Support for Conquer Cancer®, the ASCO FoundationPress ReleaseJune 24, 2024 ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative StartupsPress ReleaseMay 2, 2024 ONO PHARMA Announces Enrollment Is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSLPress ReleaseMarch 21, 2024 ONO Enters into a University-Wide, Research Alliance Agreement with Harvard UniversityPress ReleaseMarch 11, 2024 Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsPress ReleaseFebruary 13, 2024 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page Last »